NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans and Potential Partnership.

NeuroSense Therapeutics has announced plans for a Phase 3 trial for its ALS treatment, PrimeC. The company has regained Nasdaq compliance and scaled up manufacturing capabilities. Research and development expenses have decreased due to reduced clinical activity. Analysts have a Buy rating with a $7.50 price target.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, has announced significant progress in its ALS treatment pipeline. The company has regained compliance with Nasdaq's stockholders' equity requirement, scaled up manufacturing capabilities for its investigational combination therapy PrimeC, and is preparing to commence a pivotal Phase 3 trial for the treatment of amyotrophic lateral sclerosis (ALS).

The first half of 2025 has been transformational for NeuroSense. The company has successfully scaled its manufacturing capabilities to commercial levels and selected a global contract development and manufacturing organization (CDMO) to ensure supply chain readiness for potential commercialization. Additionally, NeuroSense has reported new analyses from its Phase 2b ALS study, PARADIGM, which showed promising results, including a 40% slowing of functional decline and a 74% improvement in overall survival in the per-protocol population [1].

Upcoming corporate highlights for the second half of 2025 include the submission of a Notice of Compliance with conditions (NOC/c) in Canada and the commencement of a multinational Phase 3 study of PrimeC in ALS. The company has also been advancing a binding term sheet with a global pharmaceutical partner to further the development and commercialization of PrimeC [1].

Research and development expenses for the six months ended June 30, 2025, were $2,503 thousand, a decrease of $1,230 thousand or 32.9% compared to the same period in 2024. This decrease is primarily attributed to a reduction in clinical activity. General and administrative expenses also decreased by $102 thousand or 4.4% [1].

Analysts have given NeuroSense a Buy rating with a $7.50 price target, reflecting the company's progress and potential for PrimeC to become a meaningful treatment for ALS patients [2].

References:
[1] https://www.prnewswire.com/il/news-releases/neurosense-provides-business-update-and-progress-for-the-first-half-of-2025-302518725.html
[2] Analyst rating and price target information from a financial news source.